Replies to post #129667 on DD Support Board and Research Team

[dabullishbear]

The company was founded in 2006: https://oncolixbio.com/about/management-team/

https://www.crunchbase.com/organization/oncolix
http://www.bioworld.com/content/oncolix-seeks-funding-prolactin-antagonist-trials-0

The drug Prolanta or G129R has been researched and studied by its inventor, Wen Chen, who is also an advisor to Oncolix, since 1999: https://www.ncbi.nlm.nih.gov/pubmed/10589775

https://www.ncbi.nlm.nih.gov/m/pubmed/11894130/
https://www.ncbi.nlm.nih.gov/pubmed/14647416


This is a report published in 2014 about the clinical studies/trials that were conducted on xenograft mice:
http://www.sciencedirect.com/science/article/pii/S2211124714001879

Video interview with Michael Redman:

Another article about Oncolix raising money: https://bionews-tx.com/news/2015/01/28/oncolix-raises-4-2-million-study-cancer-therapy-tetf-help/

ITOR/GHS is where they are doing their clinical trials, note that they are one of the highlighted companies along side Amgen, AstraZeneca, Eisai Pharmaceuticals, and Novartis: http://www.itor-ghs.org/pharmaceutical-industry.php

Also, in that S-1/A filing, those shares are being distributed to all of the owners and investors of Oncolix when the company was private. Oncolix is more than 70% institutional ownership. Greenville Health System, Texas Treasury Safekeeping Trust, Biovectra, Integrium. The most recent financing in that S-1/A is a private placement with companies Newbridge Securities Corporation and LifeTech Capital.